14 Feb 2013 07:00
14 February 2013
e-Therapeutics plc ("e-Therapeutics" or the "Company")
Director/PDMR Shareholding
e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, announces that on 13th February 2013 Mr Stephen Self, Development Director, purchased 20,000 shares at 32.5 pence per share. Following this purchase, Mr Self's resultant direct beneficial interest is 273,577 ordinary shares, representing 0.20% of the total issued share capital of the Company.
-Ends-
For more information, please contact:
e-Therapeutics plc
Daniel Elger
Tel: +44 (0) 79 0991 5068
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Corporate Finance: Fred Walsh / Grishma Patel
Corporate Broking: Hannah Woodley
Tel: +44 (0) 20 7886 2500
www.panmure.com
ETX.L (ETX)